Sintilimab in Cancer of Unknown Primary
A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab for Advanced Rare Cancers (SiARa Cancer Study) - Cancer of Unknown Primary (SiARa-CUP)
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
A PHASE2 clinical study on Cancer of Unknown Primary Site, this trial is completed. The trial is conducted by Innovent Biologics (Suzhou) Co. Ltd. and has accumulated 12 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE2
-
May 2025 — Feb 2026 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2025 — May 2025 [monthly]
Active Not Recruiting PHASE2
-
Nov 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 7 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Feb 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2023 — Feb 2024 [monthly]
Recruiting PHASE2
-
Mar 2023 — Sep 2023 [monthly]
Recruiting PHASE2
-
Sep 2022 — Mar 2023 [monthly]
Recruiting PHASE2
-
Sep 2021 — Sep 2022 [monthly]
Recruiting PHASE2
First recorded
Aug 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Innovent Biologics (Suzhou) Co. Ltd.
- M.D. Anderson Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .